Post-training intrahippocampal infusion of nicotine–Bucladesine (cas 16980-89-5) combination causes a synergistic enhancement effect on spatial memory retention in rats

Add time:08/07/2019    Source:sciencedirect.com

We previously had shown that bilateral intrahippocampal infusion of 1 μg nicotine (but not 0.5 μg dose) led to an improvement in spatial memory retention in the Morris water maze task in male rats. We also reported that a similar type of bilateral infusion of H89, a protein kinase AII (PKA II) inhibitor, caused a deficit in spatial memory retention. In the present study, we wished to test the hypothesis that intrahippocampal infusion of dibutyryl cyclic AMP (DB-cAMP also called bucladesine), a membrane permeable selective activator of PKA, into the CA1 region can cause an improvement in spatial memory in this maze task. Indeed, bilateral infusion of 10 and 100 μM bucladesine (but not 1 and 5 μM doses) led to a significant reduction in escape latency and travel distance (showing an improvement in spatial memory) compared to the control. Also, bilateral infusion of 0.5 μg nicotine or 1 μM bucladesine alone did not lead to an improvement in spatial memory. However, such bilateral infusion of bucladesine at 1 and 5 μM concentrations infused within minutes after 0.5 μg nicotine infusion improved spatial memory retention. Taken together, our data suggest that intrahippocampal bucladesine infusions improve spatial memory retention in male rats and that bucladesine can interact synergistically with nicotine to improve spatial memory.

We also recommend Trading Suppliers and Manufacturers of Bucladesine (cas 16980-89-5). Pls Click Website Link as below: cas 16980-89-5 suppliers

Prev:The quantitative evaluation of cholinergic markers in spatial memory improvement induced by nicotine–Bucladesine (cas 16980-89-5) combination in rats
Next:Effect of Bucladesine (cas 16980-89-5) sodium on the plasma concentrations and urinary excretion of purine bases and uridine)